{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Otto JJ"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["e2000012"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7674190"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(6)"],"pubmed_abstract":["<h4>Purpose</h4>The rs17632542 single nucleotide polymorphism (SNP) results in lower serum prostate specific antigen (PSA) levels which may further mitigate against its clinical utility as a prostate cancer biomarker. Post-digital rectal exam (post-DRE) urine is a minimally invasive fluid that is currently utilized in prostate cancer diagnosis. To detect and quantitate the variant protein in urine.<h4>Experimental design</h4>Fifty-three post-DRE urines from rs17632542 genotyped individuals processed and analyzed by liquid chromatography/mass spectrometry (LC-MS) in a double-blinded randomized study. The ability to distinguish between homozygous wild-type, heterozygous, or homozygous variant is examined before unblinding.<h4>Results</h4>Stable-isotope labeled peptides are used in the detect"],"journal":["Proteomics. Clinical applications"],"pubmed_title":["Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination."],"pmcid":["PMC7674190"],"funding_grant_id":["P30CA016042","P30 CA016042","U01CA086402","U01 CA214194","U01CA214194","P30CA054174","P50 CA211015"],"pubmed_authors":["Albracht B","Liss M","Semmes OJ","Correll VL","Otto JJ","Main BP","Yang LF","Kislinger T","Boutros PC","Hitefield NL","Leach RJ","Johnson-Pais T","Nyalwidhe JO","Engstroem HA"],"additional_accession":[]},"is_claimable":false,"name":"Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination.","description":"<h4>Purpose</h4>The rs17632542 single nucleotide polymorphism (SNP) results in lower serum prostate specific antigen (PSA) levels which may further mitigate against its clinical utility as a prostate cancer biomarker. Post-digital rectal exam (post-DRE) urine is a minimally invasive fluid that is currently utilized in prostate cancer diagnosis. To detect and quantitate the variant protein in urine.<h4>Experimental design</h4>Fifty-three post-DRE urines from rs17632542 genotyped individuals processed and analyzed by liquid chromatography/mass spectrometry (LC-MS) in a double-blinded randomized study. The ability to distinguish between homozygous wild-type, heterozygous, or homozygous variant is examined before unblinding.<h4>Results</h4>Stable-isotope labeled peptides are used in the detect","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2026-04-30T15:59:59.729Z","creation":"2021-02-20T17:42:06Z"},"accession":"S-EPMC7674190","cross_references":{"pubmed":["32614141"],"doi":["10.1002/prca.202000012"]}}